Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cefdinir

FDA-approved product (capsule, oral), marketed as Cefdinir, Omnicef.

Registered studies
32
Lab records
8
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Cefdinir
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Chronic bronchitis
  • Infection
  • Infectious otitis media
  • Otitis media
  • Pharyngitis
  • Pneumonia
  • Recurrent tonsillitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Third-generation cephalosporins
FDA pharmacologic class
Cephalosporin Antibacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01DD15; FDA class Cephalosporin Antibacterial

Repurposing investigation

Cefdinir is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA99.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli99.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae98.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis47.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

32registered studies name this medicine, for any condition. See them below.

Experimental

  • MRSA: measured active in 2 of 2 lab records
  • E. coli: measured active in 4 of 4 lab records
  • K. pneumoniae: measured active in 2 of 2 lab records
Open Cefdinir in ChEMBL Registered studies below
Show the 8 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cefdinir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Comparative, Single-Center, Pediatric Taste Test Study of Omnicef Versus Amoxicillin Antibiotic Suspension Medications

    NCT00645125 · start 2003-01

    Registered record
    Registry ID
    NCT00645125
    Conditions
    Healthy
    Interventions
    cefdinir (Omnicef); amoxicillin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-01
    Completion
    Not recorded
    Enrolment
    154

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventioncefdinir (Omnicef); amoxicillin
    PhasePhase 4
    Registry statusCompleted

  • Safety and Efficacy Study of Cefdinir Oral Suspension, in Pediatric Subjects to Treat Acute Otitis Media

    NCT00645203 · start 2002-07

    Registered record
    Registry ID
    NCT00645203
    Conditions
    Acute Otitis Media
    Interventions
    cefdinir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2002-07
    Completion
    Not recorded
    Enrolment
    447

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Otitis Media
    Interventioncefdinir
    PhasePhase 2 / Phase 3
    Registry statusCompleted